MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

NCT05264051 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2026-01-14

No results posted yet for this study

Summary

The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.

Conditions

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-18
Primary Completion
2027-03-01
Completion
2027-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05264051 on ClinicalTrials.gov